A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

NCT06460961 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm Metastasis

Interventions

BIOLOGICAL: MK-6837
BIOLOGICAL: Pembrolizumab
DRUG: Rescue Medications

Sponsor

Merck Sharp & Dohme LLC